Satralizumab reduced relapse risk by 68% in the phase III METEOROID trial for myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD), marking the first successful randomized ...
Hosted on MSN
First clinical trial in MOGAD meets primary endpoint
The interleukin-6 (IL-6) inhibitor satralizumab (Enspryng) met its primary endpoint in the phase III METEOROID trial of ...
Brazilian researchers have developed an electrochemical sensor that can detect pancreatic cancer in its early stages. The ...
Satralizumab significantly reduces relapse risk in patients with relapsing MOGAD, according to phase 3 METEOROID trial results presented at AAN 2026.
Japan's Ajinomoto has developed a plant-derived transferrin protein alternative that can significantly lower culture media ...
The trial involved adults and adolescents aged 12 years and above with MOGAD, offering an open-label extension.
Genentech, a member of the Roche Group (SIX: RO, ROP; OTCQX: RHHBY), announced today new data from the Phase III METEOROID study demonstrating that Enspryng® (satralizumab) reduced the risk of a new ...
About ENSPRYNG® (satralizumab) ENSPRYNG, which was developed by Chugai, a member of the Roche Group, is a humanised monoclonal antibody that targets interleukin-6 (IL-6) receptor activity. ENSPRYNG ...
The era of off-label guesswork for patients living with the rare autoimmune disorder MOGAD may soon be over, as a phase 3 ...
Solve Therapeutics Inc. has disclosed new antibody-drug conjugates (ADCs) comprising antibody or antigen binding fragments targeting trophoblast glycoprotein (TPBG; 5T4) linked to a cytotoxic drug and ...
Glycoprotein acetyls and phenylalanine are associated with psoriasis and joint involvement in the case of psoriatic arthritis ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results